Glivec

Glivec is a prescription oral medication whose active ingredient is imatinib. The product is marketed in the European Union and is classified as a tyrosine kinase inhibitor used in oncology. While the exact strength and dosage form are not specified, Glivec is administered by mouth and belongs to the antineoplastic therapeutic class.

Glivec is indicated for several BCR‑ABL positive malignancies and related cancers. It is commonly prescribed in the following clinical situations:

- Chronic myeloid leukemia (CML) - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL) - Gastrointestinal stromal tumor (GIST) - Other BCR‑ABL positive hematologic malignancies - Off‑label use in select solid tumors under specialist supervision

Side effects of Glivec vary in frequency and severity. Patients should be aware of both common and serious reactions.

Common: - Nausea and vomiting - Diarrhea or constipation - Fatigue or weakness - Edema, especially peripheral swelling - Muscle cramps or joint pain

Serious: - Severe liver enzyme elevation - Cardiac dysfunction or heart failure - Severe neutropenia or thrombocytopenia - Pulmonary arterial hypertension - Life‑threatening allergic reactions

Glivec requires careful monitoring and specific precautions before and during therapy. Important considerations include: - Baseline and periodic liver function tests - Regular complete blood counts to detect cytopenias - Cardiac evaluation for patients with pre‑existing heart disease - Pregnancy avoidance; the drug is category D and may cause fetal harm - Contraception for both male and female patients of reproductive potential - Monitoring for signs of fluid retention or pulmonary hypertension

Glivec can interact with several drug classes, affecting its efficacy or safety profile.

Avoid: - Strong CYP3A4 inhibitors such as ketoconazole, clarithromycin, or ritonavir - Certain antacids containing aluminum or magnesium that may reduce absorption

Use with caution: - CYP3A4 inducers like rifampin, phenytoin, or St. John's wort - Concomitant anticoagulants (e.g., warfarin) due to bleeding risk - Other myelosuppressive agents that may increase cytopenia risk - Medications that prolong QT interval